Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Byetta and Januvia cases. Here at Leading Justice, we can custom tailor your firm’s Byetta and Januvia advertising needs, and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of Byetta and Januvia advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that isn’t eligible for the target campaign is reviewed to determine whether it qualifies for another type of claim. By using innovative approaches to target contacts specifically related to pancreatic cancer and the diabetes drugs Byetta and Januvia, Leading Justice will increase your firm’s case load. If you are interested in helping victims of pancreatic cancer or pancreatitis allegedly associated with Byetta or Januvia, our extensive consumer reach and direct advertising strategies at Leading Justice give you the competitive edge and confidence you need to allocate your full budget, knowing that your money is being spent in the best way possible.
Each law firm we work with at Leading Justice has a direct impact on how we classify claims as qualified or not. And while our experience working alongside plaintiff law firms helps us recognize a great case when we see one, we will customize our Byetta and Januvia case intake specifications to the exact criteria you are seeking. If your firm has certain Byetta and Januvia qualifying case criteria you would like us to use, we will train our intake specialists to apply the criteria to each email and phone call they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of Byetta and Januvia data with no chance of fraud.
Our Take on Byetta & Januvia
Since entering the market in 2005 and 2006, respectively, Byetta and Januvia have been prescribed to millions of men and women with Type 2 diabetes in the United States. Byetta (exenatide) functions by stimulating insulin secretion from pancreatic cells, thereby lowering blood glucose levels, and Januvia (sitagliptin) works in combination with diet and exercise to lower too-high levels of glucose in the blood. Despite their widespread use, mounting research has suggested that Byetta and Januvia may have the potential to increase a patient’s risk of pancreatitis and pancreatic cancer, and one study in particular found a three-times increased risk of pancreatic cancer in Byetta patients.
The FDA has taken steps in recent years to warn consumers about the alleged link between Byetta, Januvia and devastating side effects like chronic pancreatitis, which is considered a potential cause of pancreatic cancer. Pancreatic cancer is one of the most deadly forms of cancer there is, and, according to estimates, will be diagnosed in 38,000 Americans during this year alone. Unfortunately, the prognosis for pancreatic cancer patients is grim; 74% of victims die within the first year of diagnosis, and 94% die within five years. In light of these findings, a growing number of lawsuits have been filed against the makers of Byetta and Januvia, and more claims are expected to be filed in the future.